文献速递银屑病与炎症性皮肤病

PSO-BIO-REAL:真实世界中度至重度斑块状银屑病患者使用生物制剂完全皮肤清除率的前瞻性多国观察研究

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-06-08

PSO-BIO-REAL是一项多国前瞻性观察研究,纳入846例来自美国(32%)、法国(28%)、意大利(22%)、英国(11%)和德国(8%)的度至重度斑块状银屑病患者,随访1年。结果显示,6个月和12个月时分别有23%和26%的患者达到完全皮肤清除;生物制剂初治患者完全清除率(6个月25%,12个月30%)高于经治患者(6个月和12个月均为20%)。完全清除率随既往生物制剂数量和基线合并症增加而降低。

要点

  • 真实世界中仅约四分之一患者使用生物制剂6个月后达到完全皮肤清除。
  • 生物制剂初治患者完全清除率高于经治患者。
  • 既往生物制剂数量和基线合并症越多,完全清除率越低。

核心结论

  • 真实世界中,度至重度斑块状银屑病患者使用生物制剂治疗6个月后仅四分之一达到完全皮肤清除。
  • 研究提示仍需要更有效的生物制剂以满足银屑病患者的治疗需求。

研究设计与样本

  • PSO-BIO-REAL为多国、前瞻性、真实世界、非干预性研究。
  • 共纳入846例来自美国(32%)、法国(28%)、意大利(22%)、英国(11%)和德国(8%)的度至重度斑块状银屑病患者,随访1年。
  • 纳入标准为年龄≥18岁、度至重度斑块状银屑病且已开始生物制剂治疗的患者,可为生物制剂初治或经治(转换生物制剂)。
  • 评估时间点为基线、第6个月和第12个月。

主要发现

  • 第6个月和第12个月分别有23%和26%的患者达到完全皮肤清除。
  • 研究入组前60%的患者为生物制剂初治。
  • 生物制剂经治患者完全皮肤清除率在第6个月和第12个月均为20%,低于初治患者的第6个月25%和第12个月30%。
  • 完全皮肤清除率随既往生物制剂数量和基线合并症增加而降低。

临床怎么用

  • 真实世界数据提示生物制剂治疗6个月完全皮肤清除率有限,临床应合理设定治疗预期。
  • 对生物制剂经治及合并症较多的患者,需更积极评估疗效并考虑优化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-tumour necrosis factor (TNF) and anti-interleukin (IL)-12/23 biologics revolutionized plaque psoriasis treatment by enabling ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) in clinical trials. Modern biologics are now reported to achieve PASI 100 (complete skin clearance) in clinical trials. However, real-world evidence of skin clearance rates with biologics is limited. PSO-BIO-REAL was conducted to understand the real-world burden of plaque psoriasis. OBJECTIVE: The primary objective of this observational study was to estimate the proportion of patients who achieved complete skin clearance at 6 months. Secondary objectives included maintenance of response and evaluation of complete skin clearance at 12 months. METHODS: PSO-BIO-REAL was a multinational, prospective, real-world, non-interventional study of skin clearance and patient-reported outcomes (PROs) with biologics. A total of 846 patients from the United States (32%), France (28%), Italy (22%), the United Kingdom (11%) and Germany (8%) were enrolled and followed for one year. Eligible patients were aged ≥18 years with moderate-to-severe plaque psoriasis who had initiated a biologic for plaque psoriasis. Patients could be biologic-naïve or switching biologics (biologic-experienced). Assessments were made at baseline and at months 6 and 12. RESULTS: At 6 and 12 months, 23% and 26% of patients achieved complete skin clearance, respectively. Prior to study entry, 60% were biologic-naïve. The proportion of patients achieving complete skin clearance was lower among biologic-experienced patients (20% at both months 6 and 12) compared with biologic-naïve patients (25% at month 6, 30% at month 12). The rate of complete skin clearance decreased as the number of prior biologics and baseline comorbidities increased. CONCLUSION: Only one in four patients achieved complete skin clearance after 6 months of treatment with biologics. The study indicates there still is an unmet need for more efficacious biologics for patients with psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020. PMID: 32364296. doi:10.1111/jdv.16568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。